$BTTX .013 :In February 2024, the FDA granted Better Therapeutics Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. We are actively seeking strategic partnerships to expedite the development and commercialization of this therapy.
All posts are my opinion and are not recommendations to buy or sell
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.